Genome-wide screening identified 96 and 93 genes for cisplatin and doxorubicin in triple-negative breast cancer, suggesting potential therapeutic targets to combat chemoresistance.
Key Points
Genome-wide screening revealed 96 and 93 genes that could re-sensitize TNBC to cisplatin and doxorubicin, respectively.
The analysis focused on the MDA-MB-231 cell line, showing its significant role in studying chemoresistance.
CRISPR-Cas9 genome screening and double-knockout techniques were employed to explore cancer pathways in TNBC.
Findings suggest that targeting synthetic lethal gene pairs may provide a new strategy to overcome chemoresistance.